Patients do as well on generic antiplatelet drugs as more expensive brand-name product

March 13, 2018, American Heart Association

Generic anti-platelet drugs seem to work as well as a brand name drug for heart patients, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

When a Canadian health system switched from prescribing the brand-name anti-platelet drug Plavix to a far-cheaper generic version, and chest pain were no more likely to die from any cause or be re-hospitalized for a attack or unstable angina within a year than those prescribed Plavix (17.9 percent vs. 17.6 percent).

In addition, there were no significant differences between the drug groups in the percent of patients who died or were hospitalized for any reason; had a stroke or ; or who developed bleeding as a side effect of treatment.

"People can safely use generic clopidogrel. This large and real-world study should be reassuring to physicians and healthcare organizations who have been concerned about changing what is prescribed," said Dennis T. Ko, M.D., M.Sc., lead study author and senior scientist at the Institute for Clinical Evaluative Sciences (ICES) in Toronto.

In Canada and the United States, generic drugs are approved based on small studies in healthy people showing that the active ingredient is released at equivalent levels and over the same timeframe. That suggests, but doesn't prove, that the generic product will also have the same safety and medical benefit.

Clopidogrel is used to treat patients with , , stroke or peripheral vascular disease.

Researchers compared outcomes in patients (average age 77, 57 percent male) who were prescribed clopidogrel after hospitalization for a heart attack or heart-related chest pain (unstable angina) in Ontario, Canada, where the Ministry of Health began to automatically substitute generic clopidogrel for Plavix once the brand name drug's patent expired in 2012. Between 2009 and 2014, 12,643 patients were prescribed Plavix and 11,887 generic clopidogrel.

Plavix cost about $2.58 Canadian dollars per pill in 2010 and was projected to cost the Ontario Drug Benefit Program $72.8 million by 2012. But by switching to a generic, which costs $0.39 per pill in 2018, the expense was only $19 million Canadian dollars.

"Plavix was one of the most commonly used drugs in cardiology, so switching to generics can reduce a lot of cost for individuals and health systems," said Ko, who is also a cardiologist at the Schulich Heart Centre of the Sunnybrook Health Sciences Centre at the University of Toronto.

While the study was conducted in Canada, the results should apply to the United States, even if the generic offerings are slightly different, according to the researchers.

"There are quite a few different generic brands. In this study, we considered them as a group, but later found no differences in outcome when we compared between different generics," said co-principal investigator Cynthia Jackevicius, Pharm.D., M.Sc., professor of pharmacy at Western University of Health Sciences and senior adjunct scientist at ICES.

The American Heart Association recommends clopidogrel—sometimes in combination with other drugs—for patients who have had acute coronary syndrome ( or heart attack) or stroke.

Explore further: Plavix's new generic status could be boon for patients

More information: Circulation: Cardiovascular Quality and Outcomes (2018). DOI: 10.1161/CIRCOUTCOMES.117.004194

Related Stories

Plavix's new generic status could be boon for patients

May 15, 2012
(HealthDay) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.

Generic versions of plavix approved

May 18, 2012
(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.

Personalized approach to selecting antiplatelet drugs improves outcomes

March 12, 2018
Patients with acute coronary syndrome experienced a substantially lower rate of heart attack, stroke, death from cardiovascular causes and major bleeding at 12 months if genetic information was used to inform the selection ...

Adverse events spike after blood pressure meds go generic in Canada

October 3, 2017
One month after generic versions of three widely-used blood pressure drugs became available in Canada, hospital visits for adverse events spiked in generic drug users, according to new research in Circulation: Cardiovascular ...

More potent anti-clotting drugs with angiography may benefit patients with acute chest pain

August 15, 2013
Current methods to treat acute coronary syndrome conditions, such as heart attack, include artery-clearing procedures (e.g., percutaneous coronary intervention or coronary artery bypass grafting) with medications, or medications ...

Recommended for you

Effective drug delivery to heart with tannic acid

September 18, 2018
Typical methods of drug delivery to the heart require surgical procedures involving incisions in the chest wall and bones. To efficiently treat cardiovascular and related vascular diseases without surgery, a KAIST research ...

Daily low-dose aspirin found to have no effect on healthy life span in older people

September 16, 2018
In a large clinical trial to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous cardiovascular events, aspirin did not prolong healthy, independent living (life free of dementia ...

Financial incentives for cholesterol control may be cost-effective

September 14, 2018
A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins (LDL) cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease ...

Apple's smartwatch has a heart monitor now

September 13, 2018
There will soon be another way to monitor your heart—from your wrist.

3-D virtual simulation gets to the 'heart' of irregular heartbeats

September 12, 2018
In a proof of concept study, scientists at Johns Hopkins report they have successfully performed 3-D personalized virtual simulations of the heart to accurately identify where cardiac specialists should electrically destroy ...

Dairy consumption linked to lower rates of cardiovascular disease and mortality

September 12, 2018
Dairy consumption of around three servings per day is associated with lower rates of cardiovascular disease and mortality, compared to lower levels of consumption, according to a global observational study of over 130,000 ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.